http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2538699-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf55d0a88f05b95fbd01f520b5ba93f2 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4164 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-717 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-02 |
| filingDate | 2013-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7783bfc469e659a48a7803a3054f369 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_54c4a4d80a27ffb3aab8b1e75c6c08a8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_760b44e7730009ceaa919beabb138f99 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb025c9fca18402981d0d719035b5f9c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f96741c7a6123175b698fa025c580637 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4e464992c49ed1955711535b2dad074c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e2a06c17685f2d63eeecb4ab745d4d1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e2495f6d0c15c889f92c047476e3beb9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f697eab879bac76656e57bf658b3314 |
| publicationDate | 2015-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2538699-C1 |
| titleOfInvention | Pharmaceutical composition for treating individuals suffering xerostomia |
| abstract | FIELD: medicine. n SUBSTANCE: pharmaceutical composition contains recombinant interferon specified in a group: recombinant interferon alpha, recombinant interferon beta, recombinant interferon gamma, metronidazole, hypromellose, antiseptics and a consistency base in the following relation of ingredients, g per 1 ml of the mixture: recombinant interferon, IU 100-10,000,000; metronidazole 0.00001-0.5; hypromellose 0.00001-0.5; antiseptics 0.00001-0.5; consistency base - the rest. Besides, the pharmaceutical composition contains antibiotics specified in a group: baneocin, levomycin, tetracycline, amoxicilline in an amount of 0.00001-0.5 g. Besides, the pharmaceutical composition contains antiseptics specified in a group: boric acid, salicylic acid, hydrogen peroxide, chlorhexidine, ethanol, povidone iodine, silver nitrate, silver sulphadiazine in an amount of 0.00001-0.5 g. Besides, the pharmaceutical composition contains anesthesin or lidocaine as local anaesthetics in an amount of 0.00001-0.5 g. Besides, the pharmaceutical composition contains vitamin A or beta-carotene as food colorants in an amount of 0.00001-0.5 g. Besides, the pharmaceutical composition contains flavouring agents specified in a group of: tea tree oil, menthol oil, eucalyptus leaf oil in an amount of 0.00001-0.5 g. Besides, the pharmaceutical composition contains macrogol 400, or macrogol 1500, or macrogol 4000 as a consistency base. n EFFECT: more effective treatment. n 7 cl, 11 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107513014-A |
| priorityDate | 2013-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 84.